SG
ADXN

StoneX Group’s Addex Therapeutics ADXN Stock Holding History

StoneX Group’s Portfolio ADXN Stock Details ADXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-750
Closed -$9.45K – 446
2022
Q4 		$9.45K Buy
+750
New +$11.1K ﹤0.01% 452

Other funds holding ADXN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

StoneX Group's ADXN Position: Q1 2023 in Review

StoneX Group sold out of Addex Therapeutics (ADXN) in Q1 2023, closing a stake of 750 shares — an estimated $9.45K sold.

StoneX Group first reported a position in ADXN in Q4 2022 and held it in 1 quarter. The position peaked at $9.45K in Q4 2022. 7 funds tracked by Wall St. Rank hold ADXN as of Q1 2023.

  • StoneX Group reported no remaining Addex Therapeutics position as of Q1 2023 after selling out during the quarter.
  • StoneX Group sold 750 Addex Therapeutics shares in Q1 2023, an estimated $9.45K.
  • StoneX Group first reported a position in Addex Therapeutics in Q4 2022 and held it in 1 quarter.
  • StoneX Group's Addex Therapeutics position peaked at $9.45K in Q4 2022.
  • 7 funds tracked by Wall St. Rank held Addex Therapeutics as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.